Qyuns Therapeutics is a biopharmaceutical company focus on the development of high-quality antibody drugs for the treatment of autoimmune disease. Our mission is to improve patient access to advanced and affordable medicine through science and innovation. Qyuns Therapeutics was founded in 2015 in China Medical City(Taizhou). Our two co-founders possess over 20 years experience in development therapeutic antibody drugs. We have assembled a team of highly-skilled talents with extensive experience across drug development, CMC, quality and compliance. We have eight programs under research and development, three programs are currently in phase I clinical study.
The application for clinical trial of innovative drug QX005N injection was officially accepted by the national medical products administration on April 9, 2020, with the acceptance number CXSL20000066...